Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

NCT03225846 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

88

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Huntington's Disease

Interventions

DRUG: WVE-120102
DRUG: Placebo

Sponsor

Wave Life Sciences Ltd.